重症肥胖与非肥胖脓毒症患者哌拉西林-他唑巴坦血药浓度反复监测及剂量不足与过量的风险
这项前瞻性比较研究纳入11例重度肥胖(BMI>35 kg/m²)和12例非肥胖(BMI<30 kg/m²)的严重脓毒症或脓毒性休克危重患者,均接受哌拉西林-他唑巴坦16 g/2 g/24 h持续静脉输注,7天内每12小时测哌拉西林血药浓度。肥胖组血药浓度高于64 mg/L的时间分数为64%(43-82%),非肥胖组为93%(85-100%),p=0.027;非肥胖组5例、肥胖组2例出现潜在毒性血药浓度。蒙特卡洛模拟显示目标64 mg/L时,12 g/1.5 g/24 h两组均不足,16 g/2 g/24 h仅非肥胖组足够。作者认为最危重患者可能需要哌拉西林药物监测。
要点
- 重症肥胖脓毒症患者用16 g/2 g/24 h持续输注哌拉西林时,血药浓度高于64 mg/L的时间分数为64%(43-82%),显著低于非肥胖患者的93%(85-100%),p=0.027。
- 非肥胖组5例、肥胖组2例出现潜在毒性哌拉西林血药浓度,提示高剂量持续输注下过量风险同样存在。
- 蒙特卡洛模拟显示,目标64 mg/L时12 g/1.5 g/24 h在肥胖与非肥胖组均不足,16 g/2 g/24 h仅非肥胖组足够。
- 作者认为,对血药浓度不可预测、面临过量、毒性、剂量不足和治疗失败风险的最危重患者,可能需要哌拉西林药物监测。
适用人群与场景
- 连续纳入的重症肥胖(BMI>35 kg/m²)与非肥胖(BMI<30 kg/m²)危重患者,诊断为严重脓毒症或脓毒性休克。
诊断标准与关键阈值
- 以哌拉西林血浆浓度高于64 mg/L(为铜绿假单胞菌最低抑菌浓度的4倍)的时间分数作为药效学目标。
处置流程与药物剂量
- 两组均接受哌拉西林-他唑巴坦16 g/2 g/24 h持续静脉输注。
- 7天研究期内每12小时采血,用高效液相色谱法测定哌拉西林血浆浓度。
研究设计与关键结果
- 前瞻性比较研究,纳入11例重度肥胖和12例非肥胖危重患者,共获取294份血样。
- 哌拉西林血药浓度随时间变化在两组间无统计学显著差异。
- 血药浓度高于64 mg/L的时间分数:肥胖组64%(43-82%)vs 非肥胖组93%(85-100%),p=0.027,存在组内和组间变异。
- 非肥胖组5例、肥胖组2例出现潜在毒性哌拉西林血药浓度。
- 蒙特卡洛模拟(5000次)显示,目标64 mg/L时,12 g/1.5 g/24 h在两组均不足,16 g/2 g/24 h仅非肥胖组足够。
证据类型、等级与局限
- 证据类型:前瞻性比较研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,使用16 g/2 g/24 h持续输注时,肥胖患者面对高最低抑菌浓度病原体时比非肥胖患者更可能出现哌拉西林剂量不足。
- 作者认为,对血药浓度不可预测、面临过量、毒性、剂量不足和治疗失败风险的最危重患者,可能需要哌拉西林药物监测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese critically ill patients. We aimed to compare pharmacokinetics of piperacillin in severely obese and nonobese patients with severe sepsis or septic shock. We hypothesized that plasma concentration variability would expose the critically ill to both piperacillin under and overdosing.
METHODS: Prospective comparative study. Consecutive critically ill severely obese (body mass index, > 35 kg/m) and nonobese patients (body mass index, < 30 kg/m) were treated with 16 g/2 g/24 hr continuous piperacillin-tazobactam infusion. Piperacillin plasma concentration was measured every 12 hours over a 7-day period by high-pressure liquid chromatography. Unbound piperacillin plasma concentration and fractional time of plasma concentration spent over 64 mg/L (4-fold the minimal inhibitory concentration for Pseudomonas aeruginosa) were compared between the two groups. We performed 5,000 Monte Carlo simulations for various dosing regimens and minimal inhibitory concentration and calculated the probability to spend 100% of the time over 64 mg/L.
RESULTS: We enrolled 11 severely obese and 12 nonobese patients and obtained 294 blood samples. We did not observe a statistically significant difference in piperacillin plasma concentrations over time between groups. The fractional time over 64 mg/L was 64% (43-82%) and 93% (85-100%) in obese and nonobese patients, respectively, p = 0.027 with intra- and intergroup variability. Five nonobese and two obese patients experienced potentially toxic piperacillin plasma concentrations. When 64 mg/L was targeted, Monte Carlo simulations showed that 12 g/1.5 g/24 hr was inadequate in both groups and 16 g/2 g/24 hr was adequate only in nonobese patients.
CONCLUSION: Using a conventional dosing of 16 g/2 g/24 hr continuous infusion, obese patients were more likely than nonobese patients to experience piperacillin underdosing when facing high minimal inhibitory concentration pathogens. The present study suggests that piperacillin drug monitoring might be necessary in the sickest patients who are at the highest risk of unpredictable plasma concentration exposing them to overdose, toxicity, underdosing, and treatment failure.
参考来源
- Jung B, Mahul M, Breilh D, et al. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing. Crit Care Med. 2017. PMID: 28240688. doi:10.1097/CCM.0000000000002287
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。